MC-Val-Cit-PAB-MMAE

MC-Val-Cit-PAB-MMAE

MC-Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate. It contains a thio reactive maleimidocaproyl (MC) group, a protease-sensitive Val-Cit dipeptide, a PABC linker and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells. Please contact us for GMP-grade inquiries.

Molecular structure of the compound BP-23969
    • Unit
    • Price
    • Qty
    • 10 MG
    • $210.00
    • 25 MG
    • $430.00
    • 100 MG
    • $750.00
    • 250 MG
    • $1200.00

Usually ships within 24 hours.

Would you like to inquire about custom quantity?
Inquire

Product Citations

  1. Esteban C and Veysel K. Synthesis and Enhanced Cellular Uptake In Vitro of Anti-HER2 Multifunctional Gold Nanoparticles. Cancers. 2019 June; 11(6): pp. 870.
    https://www.mdpi.com/2072-6694/11/6/870
  2. Nervig, C. S., Rice, M., Marelli, M., Christie, R. J., & Owen, S. C. (2025). Modular Synthesis of Anti-HER2 Dual-Drug Antibody-Drug Conjugates Demonstrating Improved Toxicity. Bioconjugate Chemistry.
    https://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.4c00398
  3. Roberts, S. E., Martin, H. L., Al-Qallaf, D., Tang, A. A., Tiede, C., Gaule, T. G., ... & Tomlinson, D. C. (2024). Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles. Iscience, 27(8).
    https://www.cell.com/iscience/fulltext/S2589-0042(24)01686-9